We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
48 hedge funds and large institutions have $243M invested in Entrada Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
4% more funds holding
Funds holding: 46 → 48 (+2)
1.52% more ownership
Funds ownership: 81.29% → 82.81% (+1.5%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
44% less capital invested
Capital invested by funds: $434M → $243M (-$191M)
Holders
48
Holders Change
+2
Holders Change %
+4.35%
% of All Funds
0.76%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
8
Increased
14
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.34M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.08M |
| 3 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
+$1.86M |
| 4 |
State Street
Boston,
Massachusetts
|
+$751K |
| 5 |
Walleye Capital
New York
|
+$479K |
